Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by bfwon Nov 13, 2017 7:34pm

110 Views

Post# 26955584

RE:RE:RE:PDUFA date rxtended to April 3 2018

CandideV007 wrote: Three months prior to the orignal PDUFA date, the share price was in the same range as it is now. I expect the share price to go down, but -17% is an estimation to big IMO.

bfw wrote:

palinc2000 wrote: On manufacturing issues

Well, that seriously sucks for the share price short term.

Long term I don’t see an issue but short term I would expect a big volume day down to the $6 range.

bfw

Well, I suppose we can watch the Taimed share price tonight to gage the market response.

It is not positive news.

The only silver lining is that is still appears that the FDA wants to approve the drug (this is not a CRL) as this seems a technicality in some respect.

bfw

Bullboard Posts

How one company is disrupting PoC testing